Ann: Suspension from Official Quotation, page-146

not sure if many of you have holdings in other medtechs and biotechs but when I look at those i hold and have held i cant think of one that didnt have i some aspect delays or set backs or in some cases outright failures.
Just reading RAP annual report :
the company has been listed for ~4 years
2019 revenue ~$95K, 2018 revenue ~$87K.
Not sure exactly how much raised for clinical trials for the cough app but a fair bit from memory, and had some clinical failures.
Now after 4 years it finally has its first CE approval for 1 indication.
2019 Net Loss for Period ~$5.44M; 2018 Net loss for period ~$6.53M

What they have going for them is loyal shareholders up and down.

Pretty happy that Gmed has clinical trial successes, many Regulatory approvals granted, and owns a china facility and some revenue generating USA operations. feels like the ranters on here probably caught on the wrong side of a trade otherwise they would understand the sector they are investing in more so and what it takes to get new products into a new market.